20 de February, 2022
20 de April, 2022
11:59 PM
Optimising effectiveness in patients of existing prescription drugs for major diseases (except cancer) with the use of biomarkers
Investigación
Escuela de Medicina y Ciencias de la Salud
Aplica para Diferentes Paises
Comisión Europea
EUR 35 000 000
Biomarkers/ Technology/ Drug prescription
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 “Unlocking the full potential of new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim for delivering results that are directed, tailored and contributing to all of the following expected outcomes:
Diagnostics industries move towards market approval for companion diagnostics.
Regulatory authorities approve companion diagnostics and make recommendations for the prescription of existing drugs.
Health care providers use biomarkers with existing pharmaceuticals to treat more efficiently and cost-effectively patients, with less adverse effects.
Low- and middle-income countries
Objetivo/Descripción
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 “Unlocking the full potential of new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim for delivering results that are directed, tailored and contributing to all of the following expected outcomes:
Diagnostics industries move towards market approval for companion diagnostics.
Regulatory authorities approve companion diagnostics and make recommendations for the prescription of existing drugs.
Health care providers use biomarkers with existing pharmaceuticals to treat more efficiently and cost-effectively patients, with less adverse effects.
Elegibilidad (Requisitos para elegibilidad)
Low- and middle-income countries